CEO Denis Lacombe exposed the fundamental value of EORTC at CRM Clinical Connect meeting Clinical Research MY. EORTC is unique...
- Independence
- Multidisciplinary
- Multi-tumors
- International
- Regulatory compliance

You just nailed it perfectly Dr Goh Bak Leong. EORTC Clinical Research MY

Superb exchange on clinical trials infrastructure and international collaboration with Clinical Research MY EORTC with EORTC CEO Denis Lacombe.

📹 Dr. Pawel Rajwa talks to Prof. tombal and Prof. Nick James about selecting optimal therapy for men with synchronous mHSPC. Discover the currently available treatments & know more about therapy objectives 👇

prostate.uroonco.uroweb.org/video/manageme…

#prostatecancer #oncology

Donal Hollywood award winner at #ESTRO24
Piet Ost for the STORM trial
Congrats to Thomas Zilli and all contributors 👏

Piet Ost Thomas Zilli Chad Tang, MD Shankar Siva Pierre Blanchard, MD Paul Sargos UroToday.com Sorry to be a pest again, but there is no information to be gained...PSA is not, and has never been, a valid endpoint for ADT. From BMC paper, imaging driven by PSA and the difference built during the ADT treatment...

Very well deserved! Tom Powles has done so much for the field of oncology also before this great success and surely he will do even more in the future! An amazing oncologist!

Merch giveaway to GU Cast friends Yüksel Ürün tombal. Podcast interviews with Renu Eapen Declan Murphy will post soon Advanced Prostate Cancer Consensus Conference

Great comments by Daniel E Spratt on PSMA therapy
1. Should be treated as radiation treatment and not drug
2. Activity (not dose) should be adapted to tumor burden to ensure proper efficacy
3. Impact of fractionation needs to be studied
#APCCC24

HERE IN #APCCC24 🇨🇭
IT'S ALL ABOUT THAT PSMA

Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin Neeraj Agarwal, MD, FASCO Ravindran Kanesvaran Simon C
Eleni Efstathiou Dra. María Natalia Gandur Quiroga A/Prof. Shahneen Sandhu
Christopher Sweeney, MBBS Daniel E Spratt Howard Soule
neal shore Robert Reiter Dana Rathkopf
Colin Pritchard…

Last day of the #APCCC24 meeting!

📍Join us at #PROSCA24 in Vienna on 29-30 Nov to further discuss about some APCCC consensus statements.

📍Our programme will include a dedicated session on this matter moderated by aurelius omlin and silke gillessen Advanced Prostate Cancer Consensus Conference

Still the best definition of agressive variant prostate cancer so far #APCCC2024 Misha Beltran Ana Aparicio

PARPi in unselected patients... At least @ESMO agrees with Johann Debono #APCCC24 Joachim Mateo Elena Castro esmo.org/guidelines/esm…

Celebrating the 10th anniversary of the PEACE consortium, a European Prostate Cancer Research Group. 10 years, 10 phase III randomized trials… huge impact on patients, led by Prof Karim Fizazi. Congrats! #APCCC24

The window of opportunity for patients with BCR matters ! We should start a ARpI as soon as possible in high risk BCR patients. tombal Advanced Prostate Cancer Consensus Conference @APCCC24 OncoAlert

Another kid in the block

firstwordpharma.com/story/5849017?…

#EAU24 Efficacy/Safety of DARO + ADT + DOCE in 🇪🇺 pts in ARASENS tombal Bayer Oncology Medical UroToday.com

DARO vs PBO, 🇪🇺 pts:
📌OS: HR 0.63, 95%CI 0.48–0.83
📌TT CRPC: HR 0.31, 95%CI 0.17–0.55
📌No diff in AEs

📌Outcomes in 🇪🇺 cohort similar to 🌏

#EAU24 excellent session on prostate cancer and ADT management in 2024#Many thanks to our Chair and Experts Morgan Roupret tombal Shahrokh F. Shariat Paul Sargos

Not to be missed : with Dr James Nagarajh, Karolien Goffin Nadia Withofs

❓What's the role of teratoma in prognosis of patients with non-seminomatous germ cell cancer! An IGCCCG consortium study;
🧍6792 patients with metastatic testicular NSGCT, 47% had teratoma in th primary, and 53% did not!
↘️ Presence of teratoma in primary tissue was associated…